The combination of durvalumab, tremelimumab, and chemotherapy can produce durable responses in patients with newly diagnosed, advanced-stage epithelial ovarian cancer, a phase 2 trial suggests.
Chemoradiotherapy does not improve overall survival, compared with chemotherapy alone, in patients with locally advanced endometrial cancer, a phase 3 trial suggests.
Patients with platinum-resistant epithelial ovarian cancer may have better overall survival if they enroll on a clinical trial than if they receive standard care.
Physician reimbursement rates for gynecologic oncology procedures have increased in recent years but have not kept up with inflation, a study suggests.
Ribociclib plus letrozole elicits responses in patients with recurrent low-grade serous carcinoma of the ovary, fallopian tube, or peritoneum, a phase 2 study suggests.